CD163 and glioblastoma: To assess our findings’ clinical relevance, we have used tissue microarrays containing 39 GBM patients to carry out the immunohistochemical analysis of PTEN, CD68 (M1 macrophage marker), and CD163 (M2 macrophage marker).